Salbutamol-induced Decrease in Augmentation Index is Related to the Parallel Increase in Heart Rate

Basic & Clinical Pharmacology & Toxicology
Antti J TikkakoskiIlkka H Pörsti

Abstract

The change in augmentation index following salbutamol inhalation has been applied to evaluate endothelial function. We examined the contribution of salbutamol-induced increase in heart rate to the observed decrease in augmentation index. Haemodynamics were recorded using whole-body impedance cardiography and continuous pulse wave analysis from tonometric radial blood pressure. All subjects (n = 335, mean age 46, body mass index 26, 48% men) were without medications with cardiovascular influences. The effects of salbutamol inhalation (0.4 mg) versus the endothelium-independent agent nitroglycerin resoriblet (0.25 mg) were examined during passive head-up tilt, as the haemodynamic influences of these compounds depend on body position. Salbutamol decreased augmentation index by ~3-4% units in supine and upright positions. Although salbutamol moderately increased cardiac index (+4.5%) and decreased systemic vascular resistance (-8.5%), the significant haemodynamic explanatory factors for decreased augmentation index in multivariate analysis were increased supine heart rate, and increased upright heart rate and decreased ejection duration (p < 0.001 for all, r2 = 0.36-0.37). Sublingual nitroglycerin decreased supine and upright augme...Continue Reading

References

Jan 1, 1994·Archives of Toxicology·S E Libretto
May 1, 1997·Critical Care Medicine·T KööbiA J Uusitalo
May 29, 1998·Circulation·P W WilsonW B Kannel
Nov 3, 1998·Cardiovascular Research·C StefanadisP Toutouzas
May 16, 2000·The Journal of Physiology·I B WilkinsonD J Webb
Jan 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Ian B WilkinsonJohn R Cockcroft
Feb 5, 2002·American Journal of Hypertension·Ian B WilkinsonJohn R Cockcroft
Jul 27, 2002·Journal of the American College of Cardiology·Christopher S HaywardPeter Collins
Feb 1, 2003·Clinical Physiology and Functional Imaging·Tiit KööbiVäinö Turjanmaa
Feb 1, 2003·Clinical Physiology and Functional Imaging·Lars LindKristina Johansson
Jun 11, 2005·Chest·Eleftherios M KallergisPanos E Vardas
Feb 28, 2007·Clinical and Experimental Pharmacology & Physiology·Harald M Stauss
Oct 14, 2008·Scandinavian Journal of Clinical and Laboratory Investigation·Anna TahvanainenIlkka Pörsti
Jan 19, 2011·Critical Care Medicine·Martin J DuffyDaniel F McAuley
Mar 23, 2011·International Urology and Nephrology·Simona HogasAdrian Covic
Jun 23, 2011·Diabetes/metabolism Research and Reviews·Luciano BernardiUNKNOWN Toronto Consensus Panel on Diabetic Neuropathy
Feb 16, 2013·Journal of Hypertension·Antti J TikkakoskiIlkka H Pörsti
Oct 12, 2013·European Journal of Clinical Investigation·Suresh KrishnamoorthyGregory Y H Lip
Nov 19, 2013·BMC Cardiovascular Disorders·Jenni K KoskelaIlkka H Pörsti
Nov 22, 2013·Journal of Atherosclerosis and Thrombosis·Lee StonerDavid S Rowlands
Nov 28, 2013·Journal of Hypertension·Pierre BoutouyrieUNKNOWN EXPLOR trialists

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.